Acrobiosystems Co

Acrobiosystems Co Retained Earnings

The Retained Earnings of Acrobiosystems Co (301080.SZ) as of Oct 21, 2026 is 402.09 M CNY. In the previous year, Retained Earnings was 334.20 M CNY — a change of 20.31% (higher).

Retained Earnings

402.09 MCNY

YoY

20.31%

Last updated:

Retained Earnings of Acrobiosystems Co is 2025 402.09 M CNY. Retained Earnings of Acrobiosystems Co was 2024 334.20 M CNY. It decreases by 20.31% higher compared to the previous year.

The Acrobiosystems Co Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2018
30.59 M CNY
Jan 1, 2019
35.87 M CNY
Jan 1, 2020
73.39 M CNY
Jan 1, 2021
225.76 M CNY
Jan 1, 2022
304.53 M CNY
Jan 1, 2023
318.43 M CNY
Jan 1, 2024
334.20 M CNY
Jan 1, 2025
402.09 M CNY
The Acrobiosystems Co Retained Earnings history
YEARRetained EarningsYoY
402.09 MCNY+20.31%
334.20 MCNY+4.95%
318.43 MCNY+4.57%
304.53 MCNY+34.89%
225.76 MCNY+207.63%
73.39 MCNY+104.57%
35.87 MCNY+17.26%
30.59 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acrobiosystems Co Stock analysis

What does Acrobiosystems Co do? Acrobiosystems Co Ltd develops biomedicine and bio-protein technology, focusing on recombinant proteins, detection services, kits, antibodies, fillers, and culture media. The company serves R&D and production sectors for drug discovery, screening, diagnostic reagents, and clinical trials across tumor, autoimmune, cardiovascular, and infectious disease areas. Its products support early drug development stages and process control in pharmaceutical manufacturing. The firm's main customers are pharmaceutical companies and research institutions requiring advanced biotech solutions for disease treatment development. The company generates revenue through the sale of recombinant proteins, detection services, and related products like kits and antibodies. These offerings are tailored for pharmaceutical firms engaged in drug development and diagnostic reagent optimization. Acrobiosystems' product portfolio targets the biopharmaceutical industry, specifically addressing needs in tumor, autoimmune, cardiovascular, and infectious disease research. The firm's services are utilized in preclinical and clinical trial phases to enhance drug development efficiency. Acrobiosystems' main products include recombinant proteins, kits, antibodies, fillers, and culture media, which are sold to pharmaceutical companies and research organizations. These entities use the products for early-stage drug discovery, verification, and optimization processes. The company's detection services support diagnostic reagent development and drug screening, directly contributing to the pharmaceutical R&D pipeline. The firm's focus on CMC (process control) for drug production ensures its offerings align with critical manufacturing stages in biopharmaceutical development. Acrobiosystems Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acrobiosystems Co stock

Retained Earnings of Acrobiosystems Co is 402.09 M CNY in 2025.

Retained Earnings of Acrobiosystems Co changed from 334.20 M CNY to 402.09 M CNY, representing a 20.31% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Acrobiosystems Co since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Acrobiosystems Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Acrobiosystems Co

All Key Metrics — Acrobiosystems Co